Antibody-Drug Conjugates
ArriVent Expands ADC Pipeline with Exclusive License for MRG007 from Lepu Biopharma
ArriVent BioPharma, Lepu Biopharma, MRG007, Antibody Drug Conjugate (ADC), Gastrointestinal Cancers, Exclusive License Agreement
Samsung Biologics Embarks on New Phase of Growth with Bio Campus II and ADC Services
Samsung Biologics, Bio Campus II, Plant 5, antibody-drug conjugate (ADC) services, capacity expansion, digital transformation, contract development and manufacturing organization (CDMO)
Daiichi Sankyo Expands Cancer Research and Manufacturing Capacity in Germany
Daiichi Sankyo, antibody-drug conjugates (ADCs), cancer research, manufacturing capacity, Germany, Pfaffenhofen facility, innovation center
Roche’s Chugai Enters $780M Deal with Swiss ADC Specialist Araris Biotech
Roche, Chugai, Araris Biotech, ADC, Antibody-Drug Conjugate, Biotech Deal
Pfizer and PostEra Expand AI-Driven Drug Discovery Partnership to Include Antibody-Drug Conjugates (ADCs)
AI-driven drug discovery, Antibody-Drug Conjugates (ADCs), Pfizer, PostEra, AI Lab, Proton platform, small molecule therapeutics, medicinal chemistry.
Merck’s Investigational ADC Zilovertamab Vedotin Enters Phase 3 with 100% Complete Response Rate in DLBCL Patients
Zilovertamab Vedotin, Antibody-Drug Conjugate (ADC), Diffuse Large B-Cell Lymphoma (DLBCL), Phase 2 Trial, Phase 3 Trial, ROR1, Merck, waveLINE Program
Gilead Partners with Tubulis to Revitalize ADC Pipeline
Gilead Sciences, Tubulis, Antibody-Drug Conjugates (ADCs), Cancer Treatment, Biotechnology Partnership
Merck and Kelun-Biotech Advance in Cancer Treatment with Exclusive License Agreement for Investigational ADC Candidates
Merck, Kelun-Biotech, Antibody-Drug Conjugates (ADC), Cancer Treatment, Exclusive License Agreement, TROP2, Nectin-4, SKB571
Ono Pharmaceutical Partners with LigaChem Biosciences for ADC Research and Development
Ono Pharmaceutical, LigaChem Biosciences, Antibody-Drug Conjugate (ADC), LCB97, ConjuAll ADC platform, Solid Tumors, Cancer Treatment
Arda Therapeutics Secures $43M Series A Funding to Pioneer ADCs for Fibrotic Diseases
Arda Therapeutics, Series A Funding, Fibrotic Diseases, Antibody-Drug Conjugates (ADCs), Eli Lilly, Andreessen Horowitz (a16z)